WeChat Mini Program
Old Version Features

Practical Management of Adverse Events in Patients Receiving Tarlatamab, a Delta-Like Ligand 3-Targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer.

Jacob M Sands,Stéphane Champiat,Horst-Dieter Hummel,Kelly G Paulson,Hossein Borghaei,Jean Bustamante Alvarez,David P Carbone,Jennifer W Carlisle,Noura J Choudhury,Jeffrey M Clarke,Shirish M Gadgeel,Hiroki Izumi, Alejandro Navarro,Sally C M Lau,Philip E Lammers,Shuang Huang,Ali Hamidi,Sujoy Mukherjee,Taofeek K Owonikoko

Cancer（2025）

Cited 0|Views4
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined